{
    "clinical_study": {
        "@rank": "3040", 
        "arm_group": {
            "arm_group_label": "Ribavirin, peginterferon, boceprevir", 
            "arm_group_type": "Experimental", 
            "description": "The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir."
        }, 
        "brief_summary": {
            "textblock": "1. A maximally tolerated dose of ribavirin can be defined in each patient with ESRD\n           undergoing hemodialysis.\n\n        2. Patients with Chronic Hepatitis C Virus (HCV)and End-Stage Renal Disease\n           (ESRD)undergoing hemodialysis will be able to tolerate and remain on treatment with\n           peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir.\n\n        3. A significant percentage of patients with chronic HCV and ESRD undergoing hemodialysis\n           can achieve rapid virologic response (RVR), extended virologic response (eRVR) and\n           sustained virologic response (SVR) when treated with peginterferon alfa-2b, the\n           maximally tolerated dose of ribavirin and boceprevir."
        }, 
        "brief_title": "A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Hepatitis C", 
            "End Stage Renal Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with ESRD will be treated with a dose escalation of ribavirin starting from 200 mg\n      everyday (QD) to a maximal tolerated dose.  Peginterferon will then be added.  Ribavirin\n      will be dose adjusted as needed.  Boceprevir will then be added.  Ribavirin will be dose\n      adjusted as needed.  Patients will be monitored for eRVR and SVR.  The study end-point is\n      eRVR."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic HCV defined by:\n\n          -  A history of a positive anti-HCV or HCV RNA for > 6 months or\n\n          -  A liver biopsy demonstrating at least portal fibrosis\n\n          -  HCV genotype 1\n\n          -  No prior treatment with any interferon or peginterferon preparation\n\n          -  ESRD undergoing hemodialysis for at least 6 months\n\n          -  Willingness not to conceive a child during treatment and for 6 months following\n             discontinuation of treatment.\n\n        Exclusion Criteria:\n\n          -  Histologic evidence of cirrhosis\n\n          -  Any co-existent liver disease\n\n          -  A platelet count < 90,000\n\n          -  A total white blood cell (WBC) < 2.5\n\n          -  An absolute neutrophil count < 1.5\n\n          -  Hemoglobin < 11 gm/dl on Epoetin-alpha\n\n          -  Positive test for anti-HIV\n\n          -  Pregnancy of the patient or their intimate partner\n\n          -  Women who are breast feeding\n\n          -  Significant cardiovascular disease\n\n          -  History of suicide intent, severe depression requiring hospitalization or significant\n             psychiatric disease\n\n          -  Malignancy within 5 years of enrollment except for squamous or basal cell skin cancer\n\n          -  Co-existent immune disorder such as lupus, rheumatoid as arthritis, colitis, Crohns\n             disease, sarcoidosis, etc.\n\n          -  Any patient in the opinion of the investigator who would not be a satisfactory study\n             candidate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731301", 
            "org_study_id": "LIV01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ribavirin, peginterferon, boceprevir", 
                "description": "Ribavirin monotherapy will be started at a dose of 100 mg daily.  After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Rebetol"
            }, 
            {
                "arm_group_label": "Ribavirin, peginterferon, boceprevir", 
                "description": "After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week.  This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression.  The dose of ribavirin will be adjusted as needed.", 
                "intervention_name": "Peginterferon", 
                "intervention_type": "Drug", 
                "other_name": "PegIntron, Rebetol and Victrelis"
            }, 
            {
                "arm_group_label": "Ribavirin, peginterferon, boceprevir", 
                "description": "Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon.  The dose of ribavirin will be adjusted as needed.", 
                "intervention_name": "Boceprevir", 
                "intervention_type": "Drug", 
                "other_name": "Victralis"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2b"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic hepatitis C", 
            "HCV", 
            "End stage renal disease", 
            "ESRD", 
            "Boceprevir", 
            "Ribavirin", 
            "Peg-interferon", 
            "Triple therapy"
        ], 
        "lastchanged_date": "November 20, 2012", 
        "location": {
            "contact": {
                "email": "mitchell_shiffman@bshsi.org", 
                "last_name": "Mitchell L Shiffman, MD", 
                "phone": "804-977-8920"
            }, 
            "facility": {
                "address": {
                    "city": "Richmond", 
                    "country": "United States", 
                    "state": "Virginia", 
                    "zip": "23226"
                }, 
                "name": "Liver Institute of Virginia"
            }, 
            "investigator": {
                "last_name": "Mitchell L Shiffman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Na\u00efve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir", 
        "overall_contact": {
            "email": "mitchell_shiffman@bshsi.org", 
            "last_name": "Mitchell L Shiffman, MD", 
            "phone": "804-977-8920"
        }, 
        "overall_contact_backup": {
            "email": "april_long@bshsi.org", 
            "last_name": "April G. Long, NP", 
            "phone": "804-977-8920"
        }, 
        "overall_official": {
            "affiliation": "Liver Institute of Virginia, Bon Secours Health System", 
            "last_name": "Mitchell L Shiffman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary end-point for evaluation will be the percentage of patients who achieve eRVR at treatment week 28.", 
            "measure": "Percentage of patients who achieve eRVR at treatment week 28", 
            "safety_issue": "No", 
            "time_frame": "28 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731301"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A. The ability to define the maximal tolerated dose of ribavirin. B. The ability to remain on peg-interferon alfa-2b, ribavirin and boceprevir for 24 weeks C. The percentage of patients who achieve SVR", 
            "measure": "Tolerability of treatment", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "source": "Liver Institute of Virginia", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Chronic Liver Disease Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Liver Institute of Virginia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}